Adjunctive Glycine for Obsessive Compulsive Disorder
Information source: Nathan Kline Institute for Psychiatric Research
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Obsessive Compulsive Disorder
Intervention: glycine (Dietary Supplement); placebo powder (Other)
Phase: N/A
Status: Completed
Sponsored by: Nathan Kline Institute for Psychiatric Research Official(s) and/or principal investigator(s): William M Greenberg, MD, Principal Investigator, Affiliation: Nathan Kline Institute for Psychiatric Research
Summary
The purpose of this study is to determine whether individuals with obsessive compulsive
disorder who will take a preparation of the amino acid glycine in addition to their current
treatment, may experience improvement in their symptoms.
Clinical Details
Official title: Adjunctive Glycine for Obsessive Compulsive Disorder
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Y-BOCS (Yale-Brown Obsessive Compulsive Scale)
Secondary outcome: NIMC-OC scaleCGI-Improvement QLS(Quality of Life Scale) Sheehan Disability Scale
Detailed description:
Individuals with obsessive compulsive disorder (OCD) often find inadequate relief, even with
the best of currently available treatments. Some evidence suggests the the neurotransmitter
glutamate may be a useful target for new treatments for OCD. The amino acid glycine, if
given orally in adequate dosages, can have specific effects on one particular glutamate
receptor molecule in the brain, that might be helpful with OC symptoms. This randomized,
double-blind protocol will have study participants who suffer with OCD take either a glycine
preparation or placebo for 12 weeks. Clinical measures (e. g., Y-BOCS, NIMH-OC) will be
recorded at each visit to determine whether those taking the glycine experience clinical
benefit.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosis of OCD present for at least 1 year
- Male or female, age 18 to 65
- Stable medication regimen for 12 weeks prior to study entry
- at least moderately severe OC symptoms
Exclusion Criteria:
- Active substance use disorder within the last 6 months
- Comorbid schizophrenia, schizoaffective disorder, bipolar disorder, tic disorder,
Tourette Disorder, schizotypal personality disorder
- Hoarding as the principal OCD symptom
- Insulin-dependent diabetes mellitus
- Pregnant or breastfeeding
Locations and Contacts
The Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962, United States
Additional Information
Starting date: June 2004
Last updated: August 21, 2007
|